Arcutis Biotherapeutics, Inc.
- ARQT
- NASDAQ
- Biotechnology
- Dermatology Medications
- Topical Formulations
$31.89
Today +10.65%Quote Oct 19, 2026, 08:00 PM UTC
+25.65%over the last month
Max drawdown −13.9%From 1-month high 0.0%3 months +12.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis.
Where the money comes from
Q4 2023 revenue $21.5M
- Product$21.1M98.0%
- Other Revenue$420,0002.0%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
354
Market value
$4.01B
Quote Oct 19
Floor
$31.87
0.1% below price
Resistance
$32.76
2.7% above price
Price vs analyst targets
12 analysts
Lowest target
$38.00Highest target
$48.00
$38.00Highest target
$48.00
- Price $31.89
- Average target $42.25
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 32% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ARQTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free